Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical Needs NASHVILLE, Tenn., April 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apotex"), the largest Canadian based pharmaceutical company to integrate their branded U.S. businesses.